Company news
Yabao Pharmaceutical Group Co. Ltd. news in 2026
Yabao Pharmaceutical Group Co. Ltd.'s news releases, calls and decks from 2026, newest first.
(600351)"Yabao Pharmaceutical Group Co., Ltd."Announcement on Progress in Repurchasing Shares through Call Auction
November 2, 2026
(600351)"Yabao Pharmaceutical Group Co., Ltd."Report for Q3 2026
October 27, 2026
(600351)"Yabao Pharmaceutical Group Co., Ltd."Announcement on Use of Idle Self-owned Funds for Entrusted Wealth Management
October 27, 2026
(600351)"Yabao Pharmaceutical Group Co., Ltd."Announcement on Stock Collateralized Repo Trading by Controlling Shareholder
October 27, 2026
(600351)"Yabao Pharmaceutical Group Co., Ltd."Announcement on Resolutions of the 3rd Meeting of the 10th Board of Directors
October 27, 2026
(600351)"Yabao Pharmaceutical Group Co., Ltd."Announcement on Progress of Capital Reduction of a Controlled Subsidiary Following the Conversion of Capital Reserve into Registered Capital and Completion of Industrial and Commercial Registration Changes
October 20, 2026
(600351)"Yabao Pharmaceutical Group Co., Ltd."Announcement on Progress of Capital Reduction of a Wholly-owned Subsidiary Following the Conversion of Capital Reserve into Registered Capital and Completion of Industrial and Commercial Registration Changes
October 19, 2026
(600351)"Yabao Pharmaceutical Group Co., Ltd."Announcement on Progress in Repurchasing Shares through Call Auction
October 8, 2026
Announcement on Share Pledge Repurchase Transaction by Controlling Shareholder
September 16, 2026
Announcement on Initial Repurchase of Shares through Call Auction
September 11, 2026
Announcement on Adjustment of Upper Limit of Share Repurchase Price Following Implementation of Dividend Distribution for the First Half of 2026
August 28, 2026
Announcement on Implementation of Dividend Distribution for the First Half of 2026
August 25, 2026
Announcement on the Progress of the Capital Increase in a Wholly-owned Subsidiary and the Completion of Industrial and Commercial Registration Changes
August 19, 2026
Announcement on Notifying Creditors
August 18, 2026
Announcement on Convening the 2026 Semi-annual Performance Briefing
August 10, 2026
Announcement on Shareholdings of Top 10 Shareholders and Top 10 Shareholders of Unrestricted Shares Concerning Share Repurchase
August 4, 2026
Announcement on Share Repurchase Plan through Call Auction and the Repurchase Report
July 31, 2026
Announcement on Obtaining Drug Registration Certificate
July 2, 2026
Announcement on Obtaining Notice of Approval for Drug Clinical Trials of Scopolamine Transdermal Patch
June 25, 2026
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026
June 16, 2026
Announcement on Convening Performance Briefing for 2025 and Q1 2026
June 12, 2026
Announcement on Implementation of Dividend Distribution for 2025
June 8, 2026
Announcement on Election of Employee Representative Director for the 10th Session
June 4, 2026
Announcement on Resolutions of the 15th Meeting of the 9th Board of Directors
May 28, 2026
Announcement on the Wholly-owned Subsidiary Obtaining Drug Registration Certificate
May 22, 2026
Announcement on Attending 2026 Online Collective Reception Day for Investors of Listed Companies in Shanxi Jurisdiction
May 15, 2026
Announcement on Purchasing Liability Insurance for Directors and Senior Management Members
May 7, 2026
Announcement on Resolutions of the 13th Meeting of the 9th Board of Directors
April 24, 2026
Announcement on Obtaining Drug Registration Certificate
April 20, 2026
Announcement on Implementation of Dividend Distribution for Q3 2025
January 29, 2026
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
January 16, 2026